VanEck Associates
TXG icon

VanEck Associates’s 10x Genomics TXG Stock Holding History

VanEck Associates’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,903
Closed -$83K – 1482
2026
Q1 		$83K Buy
3,903
+235
+6% +$4.7K ﹤0.01% 1313
2025
Q4 		$60K Buy
3,668
+1,695
+86% +$25.6K ﹤0.01% 1347
2025
Q3 		$23K Buy
1,973
+703
+55% +$9.17K ﹤0.01% 1370
2025
Q2 		$15K Hold
1,270
– – ﹤0.01% 1366
2025
Q1 		$11K Hold
1,270
– – ﹤0.01% 1358
2024
Q4 		$18K Sell
1,270
-114
-8% -$1.8K ﹤0.01% 1343
2024
Q3 		$21K Sell
1,384
-738
-35% -$15.3K ﹤0.01% 1312
2024
Q2 		$41K Sell
2,122
-111
-5% -$2.91K ﹤0.01% 1301
2024
Q1 		$84K Buy
2,233
+325
+17% +$14.3K ﹤0.01% 1244
2023
Q4 		$107K Buy
1,908
+362
+23% +$15.8K ﹤0.01% 1231
2023
Q3 		$64K Buy
1,546
+125
+9% +$6.5K ﹤0.01% 1262
2023
Q2 		$79K Sell
1,421
-211
-13% -$11.4K ﹤0.01% 1266
2023
Q1 		$91K Buy
1,632
+107
+7% +$5K ﹤0.01% 1248
2022
Q4 		$56K Buy
1,525
+200
+15% +$6.54K ﹤0.01% 1305
2022
Q3 		$38K Sell
1,325
-86,854
-98% -$3.31M ﹤0.01% 1284
2022
Q2 		$3.99M Buy
88,179
+9,124
+12% +$473K 0.01% 516
2022
Q1 		$6.01M Buy
79,055
+16,364
+26% +$1.43M 0.01% 469
2021
Q4 		$9.34M Sell
62,691
-2,091
-3% -$320K 0.02% 387
2021
Q3 		$9.43M Sell
64,782
-19,701
-23% -$3.38M 0.02% 353
2021
Q2 		$16.5M Sell
84,483
-6,798
-7% -$1.23M 0.04% 277
2021
Q1 		$16.5M Buy
+91,281
New +$15.8M 0.04% 256

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VanEck Associates's TXG Position: Q2 2026 in Review

VanEck Associates sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 3,903 shares — an estimated $83K sold.

VanEck Associates first reported a position in TXG in Q1 2021 and held it in 21 quarters. The position peaked at $16.5M in Q2 2021. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • VanEck Associates reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
  • VanEck Associates sold 3,903 10x Genomics shares in Q2 2026, an estimated $83K.
  • VanEck Associates first reported a position in 10x Genomics in Q1 2021 and held it in 21 quarters.
  • VanEck Associates's 10x Genomics position peaked at $16.5M in Q2 2021.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.